244 related articles for article (PubMed ID: 35593962)
1. Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis.
Fiorentino DF; Casciola-Rosen L
Clin Rev Allergy Immunol; 2022 Dec; 63(3):330-341. PubMed ID: 35593962
[TBL] [Abstract][Full Text] [Related]
2. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
4. Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature.
Poelman A; Neerinckx B; Beuselinck B; De Langhe E
Acta Clin Belg; 2023 Oct; 78(5):410-417. PubMed ID: 36847475
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
[TBL] [Abstract][Full Text] [Related]
6. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
7. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
9. Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.
Dong R; Sun Y; Xu W; Xiang W; Li M; Yang Q; Zhu L; Ma Z
Front Immunol; 2023; 14():1197458. PubMed ID: 37539050
[TBL] [Abstract][Full Text] [Related]
10. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against the NineTeen complex and U5 RNP in systemic sclerosis.
Vulsteke JB; Smith V; Bonroy C; Lenaerts JL; Derua R; Wuyts WA; Blockmans D; De Haes P; Piette Y; De Langhe E; Bossuyt X
J Autoimmun; 2023 Sep; 139():103056. PubMed ID: 37302272
[TBL] [Abstract][Full Text] [Related]
12. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract][Full Text] [Related]
13. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
14. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
[TBL] [Abstract][Full Text] [Related]
15. IMMUNOEDITING IN AUTOIMMUNE RHEUMATIC DISEASES.
Rosen A
Trans Am Clin Climatol Assoc; 2022; 132():34-43. PubMed ID: 36196176
[TBL] [Abstract][Full Text] [Related]
16. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
17. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
18. Association between clinical phenotypes of dermatomyositis and polymyositis with myositis-specific antibodies and overlap systemic autoimmune diseases.
Chiang HL; Tung CH; Huang KY; Hsu BB; Wu CH; Hsu CW; Lu MC; Lai NS
Medicine (Baltimore); 2021 Sep; 100(37):e27230. PubMed ID: 34664863
[TBL] [Abstract][Full Text] [Related]
19. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
